The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting.
Publication
, Journal Article
Cavallari, LH; Beitelshees, AL; Blake, KV; Dressler, LG; Duarte, JD; Elsey, A; Eichmeyer, JN; Empey, PE; Franciosi, JP; Hicks, JK; Holmes, AM ...
Published in: Clin Transl Sci
May 2017
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Clin Transl Sci
DOI
EISSN
1752-8062
Publication Date
May 2017
Volume
10
Issue
3
Start / End Page
143 / 146
Location
United States
Related Subject Headings
- United States
- Risk Assessment
- Practice Guidelines as Topic
- Phenotype
- Pharmacogenomic Variants
- Pharmacogenetics
- National Institutes of Health (U.S.)
- Interdisciplinary Communication
- Humans
- Genotype
Citation
APA
Chicago
ICMJE
MLA
NLM
Cavallari, L. H., Beitelshees, A. L., Blake, K. V., Dressler, L. G., Duarte, J. D., Elsey, A., … Johnson, J. A. (2017). The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting. Clin Transl Sci, 10(3), 143–146. https://doi.org/10.1111/cts.12456
Cavallari, L. H., A. L. Beitelshees, K. V. Blake, L. G. Dressler, J. D. Duarte, A. Elsey, J. N. Eichmeyer, et al. “The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting.” Clin Transl Sci 10, no. 3 (May 2017): 143–46. https://doi.org/10.1111/cts.12456.
Cavallari LH, Beitelshees AL, Blake KV, Dressler LG, Duarte JD, Elsey A, et al. The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting. Clin Transl Sci. 2017 May;10(3):143–6.
Cavallari, L. H., et al. “The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting.” Clin Transl Sci, vol. 10, no. 3, May 2017, pp. 143–46. Pubmed, doi:10.1111/cts.12456.
Cavallari LH, Beitelshees AL, Blake KV, Dressler LG, Duarte JD, Elsey A, Eichmeyer JN, Empey PE, Franciosi JP, Hicks JK, Holmes AM, Jeng L, Lee CR, Lima JJ, Limdi NA, Modlin J, Obeng AO, Petry N, Pratt VM, Skaar TC, Tuteja S, Voora D, Wagner M, Weitzel KW, Wilke RA, Peterson JF, Johnson JA. The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting. Clin Transl Sci. 2017 May;10(3):143–146.
Published In
Clin Transl Sci
DOI
EISSN
1752-8062
Publication Date
May 2017
Volume
10
Issue
3
Start / End Page
143 / 146
Location
United States
Related Subject Headings
- United States
- Risk Assessment
- Practice Guidelines as Topic
- Phenotype
- Pharmacogenomic Variants
- Pharmacogenetics
- National Institutes of Health (U.S.)
- Interdisciplinary Communication
- Humans
- Genotype